HUAKANG(SH:605077) Xin Lang Cai Jing·2026-02-10 19:00Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. has announced the cancellation of the special account for the funds raised from the issuance of convertible bonds to unspecified objects, following the completion of the intended use of the funds [1][5]. Group 1: Fundraising Overview - In 2023, the company issued 13,030,230 convertible bonds at a face value of RMB 100 each, raising a total of RMB 130,302.30 million, with a net amount of RMB 129,338.53 million after deducting issuance costs of RMB 963.77 million [2]. - The fundraising was verified by Tianjian Accounting Firm, which issued a verification report [2]. Group 2: Fund Management - The company established a management method for the raised funds to ensure compliance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3]. - A special account for the raised funds was set up in banks, and tripartite and quadripartite supervision agreements were signed with various banks and the underwriter, Dongfang Securities [4]. Group 3: Account Cancellation - As of the announcement date, the funds in the special account have been fully utilized according to the specified purposes, leading to the cancellation of the special account and the termination of related supervision agreements [5].